Hence, EpCAM-positive CTCs have been used as a prognostic biomarker in patients with various cancer types, including lung cancer [93], hepatocellular carcinoma [94], prostate cancer [95], neuroendocrine cancer [96], breast cancer [97], and colorectal cancer [98]. This evidence concerns the gene EPCAM and lung carcinoma.